Harvard Law School, J.D.
  • Harvard Environmental Law Review, Article and Technical Editor
Yale University, B.S.
  • Molecular, Cellular, and Developmental Biology

Prior Employment

  • Kirkland & Ellis, Associate, 2014-2018
    American Civil Liberties Union of Illinois, PILI Fellow, 2014
    U.S. Attorney’s Office – W.D. Washington, Summer Law Clerk, 2012

Bar Admissions

Court Admissions


  • Japanese (Intermediate)
  • Spanish (Conversational)

Professional Affiliations

American Bar Association

Harvard Law Society of Illinois

News & Resources


Cristina Almendarez is an intellectual property attorney who focuses her practice on patent infringement and trademark litigation covering a range of technology, products, and industries. Her experience includes representing clients across a range of products and technologies, including biologic and pharmaceutical drugs, consumer goods, lithium-ion batteries, medical devices, and food processing and packaging machinery.

Cristina has worked on issues across various phases of litigation, including pre-suit analysis and strategy, discovery and depositions, claim construction, summary judgment, and appeal. Her past work also includes coordination between parallel district court litigation and USPTO inter partes review proceedings.


Cristina has litigated significant life sciences-related cases, including, for example:

  • Represents named inventors of an extensive cardiac stent patent portfolio in litigation in federal court regarding breach of contract for royalties. The case is being litigated similar to a patent infringement case including the exchange of infringement and invalidity contentions, and involves a parallel inter partes review proceeding.
  • Represented Hospira, Inc., a subsidiary of Pfizer, Inc., Celltrion, Inc. and Celltrion Healthcare Co., Ltd. adverse to Janssen Biotech, Inc. in litigation in federal court related to a biosimilar version of Janssen’s multi-billion dollar drug Remicade®. The case involved the first biosimilar monoclonal antibody to be approved by the FDA, and is one of the earliest cases filed under the Biologics Price Competition and Innovation Act (BPCIA).
  • Assisted with appeals of two highly publicized motions for summary judgment that invalidated Janssen’s patent related to the infliximab antibody. The district court litigation ended with second win in the form of a judgment of non-infringement related to the second patent asserted in the case.

News & Resources


Press Releases